Agreed. I'm thinking we'll be back to a buck and potentially even lower. I'd like nothing more to revisit the .60s and .70s. A firm doesn't put 10M into a deal that is going to fail. They got access to internal data and then decided to move forward under very average (if not below average) terms.

This is a non-event if we get a PR about p53 activation.

The short term investors will look at this as a potential 10M share increase in the float but that is not bad considering the terms of the agreement. Most people don't look at the details just the headlines.